TecTraum’s pro2cool® Receives FDA Designation as a Breakthrough Device for the Treatment of Concussions
TecTraum Inc., dedicated to providing the world’s first point-of-care treatment for concussions, today announced that the U.S. Food and Drug Administration (FDA) has designated its flagship technology, pro2cool®, as a Breakthrough Device. The pro2cool System is a novel, non-invasive hypothermic therapy device designed to reduce the severity of concussion symptoms and allow patients to return to their pre-injury baseline sooner.